Market Closed -
Nasdaq
16:00:00 2024-05-07 EDT
|
5-day change
|
1st Jan Change
|
42.75
USD
|
-0.79%
|
|
+5.17%
|
+20.15%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
151.5
|
406.8
|
909.9
|
874.2
|
2,293
|
3,196
|
-
|
-
|
Enterprise Value (EV)
1 |
151.5
|
406.8
|
663.1
|
501.1
|
1,661
|
2,342
|
2,671
|
2,922
|
P/E ratio
|
-2.23
x
|
-10
x
|
-16.8
x
|
-12.8
x
|
-18.2
x
|
-19
x
|
-29.8
x
|
-17.9
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
20.8
x
|
32.6
x
|
17.2
x
|
98.1
x
|
159
x
|
23.8
x
|
36.8
x
|
EV / Revenue
|
-
|
20.8
x
|
23.7
x
|
9.84
x
|
71
x
|
116
x
|
19.9
x
|
33.7
x
|
EV / EBITDA
|
-
|
-
|
-13.7
x
|
-8.3
x
|
-12.6
x
|
-14.4
x
|
42
x
|
-17.1
x
|
EV / FCF
|
-3.84
x
|
7.4
x
|
-11.4
x
|
-5.53
x
|
-14.1
x
|
-14.8
x
|
-14.7
x
|
-14.1
x
|
FCF Yield
|
-26%
|
13.5%
|
-8.81%
|
-18.1%
|
-7.08%
|
-6.75%
|
-6.79%
|
-7.08%
|
Price to Book
|
0.93
x
|
1.75
x
|
3.02
x
|
2.15
x
|
3.29
x
|
7.13
x
|
8.43
x
|
-
|
Nbr of stocks (in thousands)
|
20,200
|
29,055
|
38,490
|
48,114
|
64,459
|
74,765
|
-
|
-
|
Reference price
2 |
7.500
|
14.00
|
23.64
|
18.17
|
35.58
|
42.75
|
42.75
|
42.75
|
Announcement Date
|
20-03-24
|
21-03-23
|
22-03-15
|
23-03-07
|
24-02-20
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
19.54
|
27.94
|
50.93
|
23.38
|
20.15
|
134.3
|
86.81
|
EBITDA
1 |
-
|
-
|
-48.54
|
-60.4
|
-132
|
-162.8
|
63.51
|
-170.6
|
EBIT
1 |
-44.27
|
-35.34
|
-50.27
|
-62.5
|
-134.4
|
-180.7
|
-112.3
|
-178.8
|
Operating Margin
|
-
|
-180.9%
|
-179.91%
|
-122.72%
|
-574.85%
|
-896.77%
|
-83.66%
|
-206.01%
|
Earnings before Tax (EBT)
1 |
-41.98
|
-34.5
|
-49.76
|
-58.66
|
-113
|
-162.6
|
-42.88
|
-164.7
|
Net income
1 |
-41.98
|
-34.5
|
-49.76
|
-58.66
|
-113
|
-168.3
|
-104.6
|
-191.9
|
Net margin
|
-
|
-176.55%
|
-178.1%
|
-115.17%
|
-483.05%
|
-835.42%
|
-77.92%
|
-221.06%
|
EPS
2 |
-3.360
|
-1.400
|
-1.410
|
-1.420
|
-1.960
|
-2.254
|
-1.433
|
-2.390
|
Free Cash Flow
1 |
-39.42
|
54.97
|
-58.42
|
-90.62
|
-117.6
|
-158
|
-181.3
|
-207
|
FCF margin
|
-
|
281.35%
|
-209.09%
|
-177.92%
|
-502.85%
|
-784.17%
|
-135.04%
|
-238.45%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-03-24
|
21-03-23
|
22-03-15
|
23-03-07
|
24-02-20
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
8.976
|
2.963
|
11.36
|
5.851
|
29.7
|
4.022
|
7.88
|
3.544
|
8.038
|
3.923
|
4.89
|
5.447
|
5.756
|
5.73
|
EBITDA
1 |
-11.26
|
-17.92
|
-13.76
|
-21.99
|
1.229
|
-25.89
|
-25.69
|
-
|
-
|
-
|
-38.59
|
-40.63
|
-42.88
|
-45.33
|
EBIT
1 |
-11.71
|
-18.37
|
-14.22
|
-22.5
|
0.66
|
-26.44
|
-26.28
|
-32.71
|
-33.53
|
-41.92
|
-51.02
|
-43.79
|
-45.6
|
-47.7
|
Operating Margin
|
-130.49%
|
-619.95%
|
-125.19%
|
-384.53%
|
2.22%
|
-657.48%
|
-333.49%
|
-922.94%
|
-417.09%
|
-1,068.44%
|
-849.08%
|
-803.98%
|
-792.16%
|
-832.45%
|
Earnings before Tax (EBT)
1 |
-11.58
|
-18.21
|
-14.01
|
-22.06
|
1.615
|
-24.2
|
-23.64
|
-27.93
|
-27.44
|
-33.96
|
-39.57
|
-40.17
|
-39.95
|
-43
|
Net income
1 |
-11.58
|
-18.21
|
-14.01
|
-22.06
|
1.615
|
-24.2
|
-23.64
|
-27.93
|
-27.44
|
-33.96
|
-39.57
|
-40.72
|
-42.75
|
-45.11
|
Net margin
|
-129.03%
|
-614.65%
|
-123.36%
|
-376.96%
|
5.44%
|
-601.72%
|
-300%
|
-787.98%
|
-341.38%
|
-865.54%
|
-802.7%
|
-747.57%
|
-742.72%
|
-787.35%
|
EPS
2 |
-0.3100
|
-0.4700
|
-0.3600
|
-0.5700
|
0.0400
|
-0.5000
|
-0.4900
|
-0.5000
|
-0.4600
|
-0.5200
|
-0.5300
|
-0.5386
|
-0.5614
|
-0.5914
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-11-15
|
22-03-15
|
22-05-10
|
22-08-15
|
22-11-08
|
23-03-07
|
23-05-09
|
23-08-10
|
23-11-07
|
24-02-20
|
24-05-07
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
247
|
373
|
633
|
854
|
526
|
274
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-39.4
|
55
|
-58.4
|
-90.6
|
-118
|
-158
|
-181
|
-207
|
ROE (net income / shareholders' equity)
|
-163%
|
-23.1%
|
-19.9%
|
-18%
|
-23.3%
|
-33%
|
-32.5%
|
-30.1%
|
ROA (Net income/ Total Assets)
|
-40.1%
|
-16.8%
|
-14.6%
|
-15.2%
|
-21.8%
|
-38.6%
|
-36.3%
|
-
|
Assets
1 |
104.8
|
205.6
|
339.8
|
384.7
|
518.6
|
436.1
|
288.2
|
-
|
Book Value Per Share
2 |
8.030
|
8.020
|
7.820
|
8.430
|
10.80
|
6.000
|
5.070
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
1.35
|
0.49
|
2.64
|
3.44
|
2.37
|
2.4
|
3.33
|
4
|
Capex / Sales
|
-
|
2.52%
|
9.46%
|
6.76%
|
10.13%
|
11.91%
|
2.48%
|
4.61%
|
Announcement Date
|
20-03-24
|
21-03-23
|
22-03-15
|
23-03-07
|
24-02-20
|
-
|
-
|
-
|
Last Close Price
42.75
USD Average target price
53.36
USD Spread / Average Target +24.83% Consensus |
1st Jan change
|
Capi.
|
---|
| +20.15% | 3.2B | | +21.74% | 46.4B | | -0.97% | 41.75B | | +49.28% | 41.37B | | -3.52% | 29.71B | | +11.12% | 26.01B | | -19.37% | 19.52B | | +31.18% | 12.43B | | -0.04% | 12.13B | | +0.39% | 12.18B |
Other Biotechnology & Medical Research
|